News headlines about Medtronic PLC (NYSE:MDT) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medtronic PLC earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave headlines about the medical technology company an impact score of 46.9591323152002 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Fidelity National Financial, Inc. (FNF) Stake Lowered by Morgan Stanley (trikkles.com)
- Medtronic plc. (NYSE:MDT) Investor Investigation over possible Violations of Securities Laws (openpr.com)
- Medtronic PLC (MDT) Shares Sold by Johnston Asset Management LLC (campdesrecrues.com)
- Medtronic PLC (NYSE:MDT) Given Consensus Rating of “Hold” by Brokerages (americanbankingnews.com)
- Medtronic PLC (NYSE:MDT) Expected to Announce Earnings of $1.08 Per Share (americanbankingnews.com)
Shares of Medtronic PLC (NYSE MDT) traded up 0.14% on Wednesday, reaching $83.95. The company’s stock had a trading volume of 3,519,268 shares. The stock has a 50-day moving average price of $86.89 and a 200-day moving average price of $82.57. The company has a market capitalization of $114.09 billion, a price-to-earnings ratio of 29.05 and a beta of 1.02. Medtronic PLC has a 1-year low of $69.35 and a 1-year high of $89.72.
Medtronic PLC (NYSE:MDT) last announced its quarterly earnings results on Thursday, May 25th. The medical technology company reported $1.33 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.02. The company had revenue of $7.92 billion for the quarter, compared to analysts’ expectations of $7.86 billion. Medtronic PLC had a net margin of 13.56% and a return on equity of 12.72%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period last year, the firm posted $1.27 earnings per share. On average, equities research analysts forecast that Medtronic PLC will post $4.81 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Wednesday, July 26th. Stockholders of record on Friday, July 7th were given a dividend of $0.46 per share. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.19%. This is a boost from Medtronic PLC’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend was Wednesday, July 5th. Medtronic PLC’s dividend payout ratio (DPR) is currently 63.67%.
Several brokerages have weighed in on MDT. UBS AG reissued a “buy” rating and issued a $95.00 price target (up previously from $94.00) on shares of Medtronic PLC in a report on Tuesday, May 30th. Jefferies Group LLC reissued a “buy” rating and issued a $103.00 price target on shares of Medtronic PLC in a report on Thursday, August 3rd. CIBC reissued a “buy” rating on shares of Medtronic PLC in a report on Friday, May 26th. Barclays PLC reissued an “overweight” rating and issued a $94.00 price target (up previously from $92.00) on shares of Medtronic PLC in a report on Sunday, May 28th. Finally, Cowen and Company reissued an “outperform” rating and issued a $95.00 price target (up previously from $86.00) on shares of Medtronic PLC in a report on Sunday, May 28th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $89.84.
In other news, EVP Bryan C. Hanson sold 12,000 shares of Medtronic PLC stock in a transaction on Monday, July 17th. The shares were sold at an average price of $88.57, for a total transaction of $1,062,840.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Richard H. Anderson purchased 5,600 shares of Medtronic PLC stock in a transaction dated Wednesday, June 21st. The shares were purchased at an average cost of $88.90 per share, for a total transaction of $497,840.00. Following the completion of the transaction, the director now owns 71,910 shares of the company’s stock, valued at $6,392,799. The disclosure for this purchase can be found here. Company insiders own 0.25% of the company’s stock.
Medtronic PLC Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.